Type 2 diabetes is a disease of insulin resistance — a metabolic condition in which cells stop responding adequately to insulin’s signal to absorb glucose from the bloodstream. Blood sugar rises. The pancreas produces more insulin to compensate. Eventually the system fails. This is the mechanism, and understanding it matters because most blood sugar medications treat the downstream consequence — elevated blood glucose — without addressing the upstream cause: why the cells stopped listening to insulin in the first place.
Metformin is the most prescribed diabetes drug in the world and has been in use since the 1950s. It has a longer track record than almost any other current pharmaceutical. It also has documented effects on B12 absorption, mitochondrial function, and the gut microbiome that are rarely discussed at the point of prescribing. The newer blood sugar drug classes — SGLT2 inhibitors, GLP-1 agonists — have different mechanisms and different undisclosed effects. This post covers the drug classes most commonly prescribed for type 2 diabetes, what they actually do, and what they do not tell you.
Important: Blood sugar management in diabetes is medically significant. Do not discontinue or alter diabetes medication without medical guidance. Uncontrolled blood sugar causes serious harm. This post is about being fully informed, not about stopping treatment.
METFORMIN — THE FULL PICTURE
Metformin’s primary mechanism is inhibition of Complex I of the mitochondrial electron transport chain in liver cells — it reduces the liver’s glucose output by impairing the mitochondrial process that powers gluconeogenesis. It also improves insulin sensitivity in peripheral tissues. The blood sugar-lowering effect is real and clinically meaningful. What the standard prescribing conversation does not cover:
B12 depletion: Metformin impairs vitamin B12 absorption from the gut by interfering with the calcium-dependent mechanism that allows B12 to be taken up in the ileum. Studies find clinically significant B12 deficiency in 10-30% of long-term metformin users, with subclinical deficiency in a higher percentage. B12 deficiency causes peripheral neuropathy — numbness, tingling, and pain in the hands and feet — cognitive decline, megaloblastic anemia, and fatigue.
Here is the critical problem: peripheral neuropathy is also a known complication of diabetes itself. When a diabetic patient on metformin develops peripheral neuropathy, it is almost invariably attributed to the diabetes — not to the drug causing B12 deficiency that causes the same symptom. The drug’s contribution to the symptom is missed, the B12 deficiency goes untreated, and the neuropathy progresses. The American Diabetes Association recommends periodic B12 monitoring for metformin users. Most patients are never told this and most are never monitored.
Mitochondrial effects: Metformin’s mechanism involves partial inhibition of mitochondrial Complex I. Mitochondria are the energy-producing organelles in every cell. Long-term, low-level mitochondrial inhibition has implications for cellular energy production beyond glucose metabolism. This is an area of active research. The drug’s interesting longevity research — findings suggesting metformin extends lifespan in animal models and is associated with reduced cancer incidence in population studies — may be related to this same mitochondrial effect through AMPK activation pathways.
Gut microbiome effects: Metformin significantly alters gut microbiome composition. Some of the blood sugar effects appear to be mediated through gut bacteria changes rather than direct cellular action. The full implications of this microbiome alteration for long-term gut health are not established.
Lactic acidosis: Rare but serious — lactic acid buildup in the blood, most likely in people with kidney impairment, heart failure, liver disease, or during acute illness or dehydration. Metformin should be held before surgical procedures and contrast dye imaging for this reason. Most patients are not clearly informed of the circumstances under which metformin becomes dangerous.
SULFONYLUREAS — THE ONES THAT WEAR OUT YOUR PANCREAS
Sulfonylureas (glipizide, glyburide, glimepiride) work by forcing the pancreas to produce more insulin regardless of blood sugar level. They are cheap and widely prescribed. The significant problem that is not prominently disclosed: they work by stimulating beta cells — the insulin-producing cells of the pancreas — to release insulin continuously. Beta cells have a finite capacity. Years of forced overstimulation accelerates beta cell burnout. Patients on sulfonylureas for years progress toward insulin dependence faster than patients on other drug classes — not because their diabetes is worsening at a faster natural rate, but because the treatment is accelerating the loss of the pancreatic capacity they had left.
Sulfonylureas also cause hypoglycemia because they drive insulin release independent of actual blood glucose levels. Hypoglycemic episodes in elderly patients cause falls, cognitive impairment, and cardiovascular stress. They are associated with weight gain. Despite these documented problems, they remain widely prescribed, largely because they are inexpensive and familiar.
SGLT2 INHIBITORS — THE NEWER CLASS AND WHAT THEY DO NOT LEAD WITH
SGLT2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Farxiga, canagliflozin/Invokana) work by preventing the kidneys from reabsorbing glucose, causing it to be excreted in urine. They genuinely lower blood sugar and have shown cardiovascular and kidney protective benefits in clinical trials — real benefits that distinguish them from older drug classes in some patients.
What does not lead the marketing: urinary tract and genital infections are significantly increased because glucose in the urine creates a growth medium for bacteria and yeast. Diabetic ketoacidosis (DKA) can occur even with relatively normal blood sugar levels in SGLT2 inhibitor users — a presentation different from typical DKA that has led to missed diagnoses and deaths. Fournier’s gangrene — necrotizing fasciitis of the genitals — is a rare but documented adverse event serious enough that the FDA issued a black box warning. Canagliflozin carries an FDA warning for increased lower limb amputation risk. These are real risks that many patients prescribed these drugs have never been told about.
GLP-1 AGONISTS — OZEMPIC, WEGOVY, AND WHAT THE HYPE OMITS
GLP-1 agonists (semaglutide/Ozempic, Wegovy; liraglutide/Victoza; tirzepatide/Mounjaro) work by mimicking glucagon-like peptide-1, a gut hormone that stimulates insulin release in response to food, suppresses glucagon, slows gastric emptying, and reduces appetite. The weight loss effects are real and significant. The cardiovascular benefits in high-risk diabetic patients are documented.
The underdiscussed picture: gastroparesis — significant slowing of stomach emptying — occurs in some users beyond the intended mild delay. Pancreatitis and pancreatic cancer signals have appeared in pharmacovigilance data. Thyroid C-cell tumors appeared in animal studies, leading to a black box warning for personal or family history of medullary thyroid carcinoma. Muscle loss is significant — rapid weight loss on GLP-1 agonists includes substantial lean muscle mass loss alongside fat loss, with implications for long-term metabolic rate and physical function. When patients stop the drug — and most do, due to cost, side effects, or insurance — the weight returns rapidly. The drug does not change the underlying metabolic condition; it manages symptoms pharmacologically for as long as it is taken.
WHAT THE EVIDENCE SAYS ABOUT LIFESTYLE VS. DRUGS
The Diabetes Prevention Program — a large NIH-funded randomized controlled trial — compared metformin to intensive lifestyle intervention (dietary change and 150 minutes per week of moderate exercise) in people with prediabetes. Lifestyle intervention reduced diabetes progression by 58%. Metformin reduced it by 31%. Lifestyle was nearly twice as effective as the drug, with no side effects and significant additional health benefits. This study is not hidden — it has been published and widely cited. It is simply not what happens in most clinical encounters, where a prescription is written in ten minutes and lifestyle counseling is minimal or absent.
For people already diagnosed with type 2 diabetes, low-carbohydrate dietary approaches have demonstrated remarkable efficacy — in some studies achieving complete remission of type 2 diabetes without medication in a substantial percentage of participants. Virta Health’s published five-year data on nutritional ketosis for type 2 diabetes showed over half of participants achieving HbA1c below the diabetic threshold while reducing or eliminating medications. Remission is possible for many people with type 2 diabetes through dietary change. This is not widely told to patients at the point of diagnosis.
SUPPORTING YOUR BODY
B12 monitoring and repletion for metformin users: Ask your doctor for annual B12 testing. Methylcobalamin (the active form of B12) is better absorbed than cyanocobalamin. Sublingual or injected B12 bypasses the gut absorption mechanism that metformin impairs. Dietary B12 sources alone may not be adequate to maintain levels in long-term metformin users.
Berberine: Multiple head-to-head clinical trials have found berberine comparable to metformin for blood sugar lowering in type 2 diabetes, with a different mechanism that does not impair B12 absorption or carry lactic acidosis risk. It also activates AMPK — the same metabolic pathway that gives metformin some of its benefits. Worth discussing with a physician for people seeking non-pharmaceutical metabolic support.
Bitter melon, gymnema sylvestre, cinnamon: Traditional hypoglycemic herbs with varying degrees of clinical evidence. Gymnema has the strongest traditional use for blood sugar and some supporting clinical research. Relevant as adjuncts in a comprehensive metabolic approach.
Dietary carbohydrate reduction: The most mechanistically direct intervention for insulin resistance is reducing the carbohydrate load that drives blood glucose elevation and the resulting insulin demand. No blood sugar drug addresses the root cause the way dietary change does.
Magnesium: Magnesium deficiency is extremely common in people with type 2 diabetes — both because low magnesium is a risk factor for insulin resistance and because elevated blood sugar causes increased urinary magnesium loss. Magnesium is a cofactor for insulin receptor function. Repletion through diet (dark leafy greens, nuts, seeds, legumes) or magnesium glycinate supplementation is relevant for anyone managing blood sugar.
Cross-reference: Know Your Medication — Statins | Know Your Food — Ultra-Processed Food | Know Your Body | Herbal Remedies | Root Cellar
FROM THE WASTELAND
Leaf Juice — Wasteland Survival Series, Book 1
Berberine-containing herbs, bitter melon preparations, gymnema, and the blood sugar-supportive herb protocols have preparation guides in Leaf Juice alongside the liver and metabolic support preparations most relevant to insulin resistance.
Paperback | Kindle